Adequate Hydration Therapy Combined With Intravenous Infusion of Isosorbide Dinitrate Prevention for CIN
Status:
Unknown status
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
Patients at moderate and high risk for contrast induced nephropathy (CIN) should receive
sufficient hydration before application of contrast to prevent CIN, but hydration could
obviously increase the preload for congestive heart failure (CHF) patients. Isosorbide
Dinitrate could reduce cardiac preload and afterload by expanding vein and artery.so adequate
hydration therapy combined with intravenous infusion of isosorbide dinitrate could better
prevent contrast-induced nephropathy theoretically.This prospective, randomized,
double-blind, comparative clinical trial randomly selected 264 patients with estimated
glomerular filtration rate, (eGFR) <60 ml/min per 1.73 m2 and CHF undergoing coronary
angiography to receive either the convention hydration (n=200) or the hydration therapy
combined with intravenous infusion of isosorbide dinitrate(n=200).